Trial Profile
A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- 12 Sep 2005 New trial record.
- 23 Jun 2005 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2005 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.